Posted by Michael Wonder on 03 Feb 2021
FDA grants accelerated approval to tepotinib for metastatic non-small cell lung cancer
3 February 2021 - Today the FDA granted accelerated approval to tepotinib (Tepmetko, EMD Serono) for adult patients with metastatic non-small cell lung cancer harbouring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.
Efficacy was demonstrated in the VISION trial, a multicenter, non-randomized, open-label, multi-cohort study enrolling 152 patients with advanced or metastatic non-small-cell lung cancer with MET exon 14 skipping alterations.
